Stay updated with breaking news from Euronext. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic...
NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function,...
D.A. Davidson & CO. increased its holdings in Invesco S&P 500 Equal Weight ETF (NYSEARCA:RSP – Free Report) by 44.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 206,644 shares of the company’s stock after purchasing an additional 63,130 shares during the […]
Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly
US stocks had a mixed day on Monday with the Nasdaq Composite hitting a record high while the Dow Jones fresh from a conquest of the the 40000 level took the day off